Levels. The Framingham Study. JAMA. 1986 Nov 28; 256(20):2835?. [PubMed: 3773200] 3. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart illness mortality in older persons. JAMA. 1995 Aug 16; 274(7):539?four. [PubMed: 7629981] 4. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular illness. Four potential American studies. Circulation. 1989 Jan; 79(1):eight?5. [PubMed: 2642759] five. Kuvin JT, Alsheikh-Ali AA, Karas RH. High-density lipoprotein cholesterol-raising approaches. J Cardiovasc Pharmacol. 2006 Feb; 47(two):196?04. [PubMed: 16495756] six. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13; 364(two):127?5. [PubMed: 21226578] 7. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov ten; 98(19):2088?three. [PubMed: 9808609] eight. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in guys with low levels of high-density lipoprotein cholesterol. Veterans Affairs HighDensity Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug five; 341(6):410?. [PubMed: 10438259]Clin Pharmacokinet. Author manuscript; obtainable in PMC 2014 August 01.Mohammadpour and AkhlaghiPage9. Shepherd J. Fibrates and statins inside the remedy of hyperlipidaemia: an appraisal of their efficacy and security. Eur Heart J. 1995 Jan; 16(1):five?three. [PubMed: 7737222] ten. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the impact of nicotinic acid alone or in mixture on cardiovascular events and atherosclerosis. Atherosclerosis. 2010 Jun; 210(2):353?61. [PubMed: 20079494] 11. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic assessment. JAMA. 2007 Aug 15; 298(7):786?8. [PubMed: 17699012] 12. Lagrost L, Gambert P, Dangremont V, et al.Formula of (6-Chloropyridazin-3-yl)methanol Part of cholesteryl ester transfer protein (CETP) inside the HDL conversion procedure as evidenced by using anti-CETP monoclonal antibodies.2-Chloro-5-hydroxyisonicotinic acid custom synthesis J Lipid Res. 1990 Sep; 31(9):1569?5. [PubMed: 2246610] 13. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000 Jul 13; 406(6792):203?. [PubMed: 10910363] 14. Clark RW, Ruggeri RB, Cunningham D, et al.PMID:23509865 Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, such as mechanism of action. J Lipid Res. 2006 Mar; 47(3):537?52. [PubMed: 16326978] 15. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and style of your dal-OUTCOMES trial: efficacy and safety of dalcetrapib in sufferers with current acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896?01. e3. [PubMed: 19958854] 16. Krishna R, Anderson MS, Bergman AJ, et al. Effect with the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in individuals with dyslipidaemia and on 24-h ambulatory blood stress in healthy folks: two double-blind, randomised placebo-controlled phase I research. Lancet. 2007 Dec eight; 370(9603):1907?4. [PubMed: 18068514] 17. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is usually a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or growing blood stress. J Lipid Res. 2011 Dec; 52(12):2169?6. [PubMed: 21957197] 18. Weber O, Willmann S, Bis.